NEOGNeogen Corporation
Is the price fair?
A demanding price: priced for +19% a year vs −1% a year delivered and at the top of its own P/E range.
Priced for ~19% a year FCF growth. The price already bakes in strong, sustained growth.
Expensive vs its own history: P/E 242.4 vs a 61.7 median over 26 quarters (+293% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What NEOG's price assumes
Neogen Corporation did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 3.01× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 1.9%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +19%
Growth the price implies · The price pays for +19% free cash flow growth a year for a decade; revenue has shrunk 1.3% a year over the last three.
- Price / book
- 1.28
Price / book · today's price, trailing year to Aug 31, 2026
Details›
- Price / booktoday's price, trailing year to Aug 31, 2026
- 1.28
- EV / EBIToperating margin −0.83%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Aug 31, 2026
- 4.57
- Free cash flow, trailing twelve months
- $50M
- Market capitalisation218.3 million shares, counted Aug 31, 2026
- $2.66B
- 3-year revenue growth
- −1.3%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.